World Health Organization Issues Warning Over Critical Shortage of Obesity Injections
Under one in 10 patients who could benefit from weight-loss injections like Wegovy have access to them, caution the global health agency as it issues its inaugural guidance on the therapies.
Given over a billion people worldwide now living with obesity, it is advocating for broader and more equitable access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a chronic disease that can be addressed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major hurdles to broad availability to the treatments that can help people shift considerable body mass, explains the agency.
GLP-1 Therapy Scarcity
Despite the present most optimistic scenario, the production of such drugs could only cover around 100 million people – less than 10% of those who need them, per the WHO.
The advice calls on governments and firms to expand access, via measures like voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
These medications imitate a natural hormone to reduce digestion speed, curb appetite and boost satiety so users consume fewer calories.
Patients usually begin shedding pounds within a few weeks of beginning the regular doses.
Studies indicates users may put most of the weight back on within a year of halting the treatment, as their usual appetite return.
To be above a healthy weight elevates your likelihood for contracting diseases, such as type 2 diabetes, heart disease, stroke, and certain cancers.
Obesity affects individuals in countries worldwide and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.
